CARsgen Therapeutics Holdings Ltd - ESG Rating & Company Profile powered by AI
This webpage of CARsgen Therapeutics Holdings Ltd is assembled by All Street Sevva using leading NLP. Other corporations in the rating peer group for CARsgen Therapeutics Holdings Ltd are shownin the table. This analysis of CARsgen Therapeutics Holdings Ltd uses data from across the internet as well as from available documents by CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 4.0, social score of 4.8 and governance score of 4.8.
4.5
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
852 | Vaccibody AS | 4.6 | High |
852 | argenx SE | 4.6 | High |
868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
868 | Boiron SA | 4.5 | High |
868 | Bonesupport Holding AB | 4.5 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does CARsgen Therapeutics Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does CARsgen Therapeutics Holdings Ltd disclose current and historical energy intensity?
Does CARsgen Therapeutics Holdings Ltd report the average age of the workforce?
Does CARsgen Therapeutics Holdings Ltd reference operational or capital allocation in relation to climate change?
Does CARsgen Therapeutics Holdings Ltd disclose its ethnicity pay gap?
Does CARsgen Therapeutics Holdings Ltd disclose cybersecurity risks?
Does CARsgen Therapeutics Holdings Ltd offer flexible work?
Does CARsgen Therapeutics Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does CARsgen Therapeutics Holdings Ltd disclose the number of employees in R&D functions?
Does CARsgen Therapeutics Holdings Ltd conduct supply chain audits?
Does CARsgen Therapeutics Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does CARsgen Therapeutics Holdings Ltd conduct 360 degree staff reviews?
Does CARsgen Therapeutics Holdings Ltd disclose the individual responsible for D&I?
Does CARsgen Therapeutics Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does CARsgen Therapeutics Holdings Ltd disclose current and / or historical scope 2 emissions?
Does CARsgen Therapeutics Holdings Ltd disclose water use targets?
Does CARsgen Therapeutics Holdings Ltd have careers partnerships with academic institutions?
Did CARsgen Therapeutics Holdings Ltd have a product recall in the last two years?
Does CARsgen Therapeutics Holdings Ltd disclose incidents of discrimination?
Does CARsgen Therapeutics Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has CARsgen Therapeutics Holdings Ltd issued a profit warning in the past 24 months?
Does CARsgen Therapeutics Holdings Ltd disclose parental leave metrics?
Does CARsgen Therapeutics Holdings Ltd disclose climate scenario or pathway analysis?
Does CARsgen Therapeutics Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does CARsgen Therapeutics Holdings Ltd disclose the pay ratio of women to men?
Does CARsgen Therapeutics Holdings Ltd support suppliers with sustainability related research and development?
Does CARsgen Therapeutics Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does CARsgen Therapeutics Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is CARsgen Therapeutics Holdings Ltd involved in embryonic stem cell research?
Does CARsgen Therapeutics Holdings Ltd disclose GHG and Air Emissions intensity?
Does CARsgen Therapeutics Holdings Ltd disclose its waste policy?
Does CARsgen Therapeutics Holdings Ltd report according to TCFD requirements?
Does CARsgen Therapeutics Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does CARsgen Therapeutics Holdings Ltd disclose energy use targets?
Does CARsgen Therapeutics Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does CARsgen Therapeutics Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for CARsgen Therapeutics Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.